The purpose of this study is to evaluate whether or not the addition of Herceptin may be of benefit to a standard regimen of carboplatin-paclitaxel.

Inclusion Criteria:

• 18 years or older; patients with histologically proven diagnosis of ovarian cancer.
• Patients with metastatic disease and an overexpression of HER2 (as determined by immunochemistry)
• Patients who have progressed while receiving treatment, or within 6 months after completion of treatment. Patients must have received carboplatin and paclitaxel.
• Patients who have received at minimum one line of chemotherapy
• 3 weeks minimum since last treatment with chemotherapy must have elapsed
• Patients must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) or an assessable cancer antigen (CA) 125 > 1.25 x upper limit of normal (ULN)
• Patients must have ECOG of 2 or less
• Left ventricular ejection fraction (LVEF) of 50% or better
• Patients have given their signed and verbal consent

Exclusion Criteria:

• Previous treatment with Herceptin or similar products affected growth factors (eg: Iressa)
• Another experimental treatment in the previous 30 days
• No overexpression of HER2 receptors
• Patients having received high-dose chemotherapy or stem-cell interventions
• Other cancers within the last 5 years
• Patients with dyspnea at rest or requiring oxygen therapy